BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1607 related articles for article (PubMed ID: 19584504)

  • 21. Prediction of drug-resistance in HIV-1 subtype C based on protease sequences from ART naive and first-line treatment failures in North India using genotypic and docking analysis.
    Toor JS; Sharma A; Kumar R; Gupta P; Garg P; Arora SK
    Antiviral Res; 2011 Nov; 92(2):213-8. PubMed ID: 21875619
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Selection of drug-resistant HIV-1 during the early phase of viral decay is uncommon in treatment-naïve patients initiated on a three- or four-drug antiretroviral regimen including lamivudine.
    Bergroth T; Ekici H; Gisslén M; Loes SK; Goh LE; Freedman A; Lampe F; Johnson MA; Sönnerborg A
    J Med Virol; 2009 Jan; 81(1):1-8. PubMed ID: 19031460
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antiretroviral drug resistance among HIV-1 infected children failing treatment.
    Mullen J; Leech S; O'Shea S; Chrystie IL; Du Mont G; Ball C; Sharland M; Cottam F; Zuckerman M; Rice P; Easterbrook P
    J Med Virol; 2002 Nov; 68(3):299-304. PubMed ID: 12226814
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Analysis of the diversity of the HIV-1 pol gene and drug resistance associated changes among drug-naïve patients in Burkina Faso.
    Tebit DM; Sangaré L; Tiba F; Saydou Y; Makamtse A; Somlare H; Bado G; Kouldiaty BG; Zabsonre I; Yameogo SL; Sathiandee K; Drabo JY; Kräusslich HG
    J Med Virol; 2009 Oct; 81(10):1691-701. PubMed ID: 19697403
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antiretroviral genotypic resistance in plasma RNA and whole blood DNA in HIV-1 infected patients failing HAART.
    Saracino A; Gianotti N; Marangi M; Cibelli DC; Galli A; Punzi G; Monno L; Lazzarin A; Angarano G;
    J Med Virol; 2008 Oct; 80(10):1695-706. PubMed ID: 18712823
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evolution of genetic diversity and drug resistance mutations in HIV-1 among untreated patients from Mali between 2005 and 2006.
    Derache A; Maiga AI; Traore O; Akonde A; Cisse M; Jarrousse B; Koita V; Diarra B; Carcelain G; Barin F; Pizzocolo C; Pizarro L; Katlama C; Calvez V; Marcelin AG
    J Antimicrob Chemother; 2008 Sep; 62(3):456-63. PubMed ID: 18556706
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Primary drug-resistance in HIV-positive patients on initiation of first-line antiretroviral therapy in Germany.
    Oette M; Kaiser R; Däumer M; Akbari D; Fätkenheuer G; Rockstroh JK; Stechel J; Rieke A; Mauss S; Schmalöer D; Göbels K; Vogt C; Wettstein M; Häussinger D
    Eur J Med Res; 2004 May; 9(5):273-8. PubMed ID: 15257882
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evidence for differences in the sexual transmission efficiency of HIV strains with distinct drug resistance genotypes.
    de Mendoza C; Rodriguez C; Corral A; del Romero J; Gallego O; Soriano V
    Clin Infect Dis; 2004 Oct; 39(8):1231-8. PubMed ID: 15486849
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term suppression of plasma viremia with highly active antiretroviral therapy despite virus evolution and very limited selection of drug-resistant genotypes.
    Pariente N; Pernas M; de la Rosa R; Gómez-Mariano G; Fernández G; Rubio A; López M; Benito JM; López-Galíndez C; Leal M; Domingo E; Martinez MA; Mas A
    J Med Virol; 2004 Jul; 73(3):350-61. PubMed ID: 15170628
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Drug-class-wide resistance to antiretrovirals in HIV-infected patients failing therapy: prevalence, risk factors and virological outcome.
    Tozzi V; Zaccarelli M; Bonfigli S; Lorenzini P; Liuzzi G; Trotta MP; Forbici F; Gori C; Bertoli A; Bellagamba R; Narciso P; Perno CF; Antinori A;
    Antivir Ther; 2006; 11(5):553-60. PubMed ID: 16964822
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Primary HIV-1 resistance in recently and chronically infected individuals of the Italian Cohort Naive for Antiretrovirals.
    Violin M; Forbici F; Cozzi-Lepri A; Velleca R; Bertoli A; Riva C; Giannella S; Manconi PE; Lazzarin A; Pasquinucci S; Tacconi L; Carnevale G; Mazzotta F; Bonazzi L; Montroni M; Chirianni A; Capobianchi M; Ippolito G; Moroni M; Perno CF; D'Arminio-Monforte A;
    J Biol Regul Homeost Agents; 2002; 16(1):37-43. PubMed ID: 12003172
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Accumulation of drug resistance and loss of therapeutic options precede commonly used criteria for treatment failure in HIV-1 subtype-C-infected patients.
    Barth RE; Aitken SC; Tempelman H; Geelen SP; van Bussel EM; Hoepelman AI; Schuurman R; Wensing AM
    Antivir Ther; 2012; 17(2):377-86. PubMed ID: 22297391
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Analysis of drug resistance-associated mutations in treatment-naïve individuals infected with different genetic forms of HIV-1 circulating in countries of the former Soviet Union.
    Vázquez de Parga E; Rakhmanova A; Pérez-Alvarez L; Vinogradova A; Delgado E; Thomson MM; Casado G; Sierra M; Muñoz M; Carmona R; Vega Y; Contreras G; Medrano L; Osmanov S; Nájera R
    J Med Virol; 2005 Nov; 77(3):337-44. PubMed ID: 16173024
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Nucleoside reverse transcriptase inhibitor resistance mutations in subtype F1 strains isolated from heavily treated adolescents in Romania.
    Paraschiv S; Otelea D; Baicus C; Tinischi M; Costache M; Neaga E
    Int J Infect Dis; 2009 Jan; 13(1):81-9. PubMed ID: 18632295
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Thymidine analogue reverse transcriptase inhibitors resistance mutations profiles and association to other nucleoside reverse transcriptase inhibitors resistance mutations observed in the context of virological failure.
    Marcelin AG; Delaugerre C; Wirden M; Viegas P; Simon A; Katlama C; Calvez V
    J Med Virol; 2004 Jan; 72(1):162-5. PubMed ID: 14635026
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Primary drug resistance in antiretroviral-naïve injection drug users.
    Tossonian HK; Raffa JD; Grebely J; Viljoen M; Mead A; Khara M; McLean M; Krishnamurthy A; DeVlaming S; Conway B
    Int J Infect Dis; 2009 Sep; 13(5):577-83. PubMed ID: 19111493
    [TBL] [Abstract][Full Text] [Related]  

  • 37. HIV-1 pol phylogenetic diversity and antiretroviral resistance mutations in treatment naïve patients from Central West Brazil.
    Cardoso LP; Queiroz BB; Stefani MM
    J Clin Virol; 2009 Oct; 46(2):134-9. PubMed ID: 19682948
    [TBL] [Abstract][Full Text] [Related]  

  • 38. HIV-1 primary and secondary antiretroviral drug resistance and genetic diversity among pregnant women from central Brazil.
    Cardoso LP; Pereira GA; Viegas AA; Schmaltz LE; Stefani MM
    J Med Virol; 2010 Mar; 82(3):351-7. PubMed ID: 20087934
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Human immunodeficiency virus type 1 protease and reverse transcriptase mutation patterns among treatment-naive patients in different stages of infection in Rio de Janeiro, Brazil.
    Varella RB; Ferreira SB; de Castro MB; Zalis MG; Tavares MD
    J Med Virol; 2007 Aug; 79(8):1033-9. PubMed ID: 17596836
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antiretroviral drug resistance and phylogenetic diversity of HIV-1 in Chile.
    Ríos M; Delgado E; Pérez-Alvarez L; Fernández J; Gálvez P; de Parga EV; Yung V; Thomson MM; Nájera R
    J Med Virol; 2007 Jun; 79(6):647-56. PubMed ID: 17457921
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 81.